

JOINT PROGRAMMING INITIATIVE ON ANTIMICROBIAL RESISTANCE

JPIAMR Strategy 2018-2020

General Information	
Acronym and name of the initiative	Joint Programming Initiative on Antimicrobial Resistance
Acronym of the initiative	JPIAMR
Weblink	www.jpiamr.eu ; twitter.com/JPIonAMR
Launch of the initiative	2011
Chairperson	Carlos Segovia, Instituto Carlos III, Spain
Chair SAB	Herman Gossens, Antwerp University
Head Secretariat	Laura Marin, Swedish Research Council, Sweden laura.marin@vr.se
Strategic research (and innovation) agenda	V1. December 2013 http://www.jpiamr.eu/activities/strategicresearchagenda/
Current Implementation plan	V2. December 2015 http://www.jpiamr.eu/activities/implementation-plan/
Funded projects	http://www.jpiamr.eu/fundedprojects/


1. JPI Vision and strategy

Antibiotics have saved millions of lives from once-deadly diseases, but through use and misuse, antimicrobial resistance (AMR) continues to spread making antibiotics useless. The prediction is that by 2050, 10 million people will die each year due to drug resistant infections. Since bacteria develop resistance naturally it is not enough to only develop new antibiotics. Instead we must focus on **reducing the incidence rates** of bacterial infectious disease, making a **rational use** of antibiotics and **cut transmission** of resistant bacteria. We must also **carry out more research** to better understand how resistance develops and spreads in the environment, develop diagnostic tools and better surveillance methods as well as validate smarter strategies to use antibiotics in health care and agriculture. This Initiative supports and coordinates research in these areas to tackle the raise of

antibiotic resistance not only in the discovery part of drug development but also in the conservation and prevention strategies.

The Joint Programming Initiative on Antimicrobial Resistance, JPIAMR, is an international platform to exchange information, identify areas of mutual interest and opportunities to work collaboratively where appropriate to add value to existing AMR activities. It coordinates national funding and supports collaborative action to fill knowledge gaps in this field. By mobilising existing and new resources, the initiative can create a greater critical mass and attract new researchers into the AMR field. A Strategic Research Agenda (SRA), which outlines key [neglected] areas to tackle, guides JPIAMR

JPIAMR'S ADDED VALUE



and focuses research actions. The SRA also serves as a guidance documents for nations to align their AMR research agenda.

As resistant bacteria know no national borders, JPIAMR works at an international scale. By engaging individual nations beyond Europe as members (22 current members), the JPIAMR platform enables collaborative actions in areas of unmet needs.

The JPIAMR thus promotes transnational cooperation to combine

the resources, infrastructures and research strengths in order to overcome the challenge of antimicrobial resistance. JPIAMR main ambition is to help to reduce antimicrobial resistance supporting scientific activities at international level to provide evidence-based solutions to the policy level; at public health and veterinarian/agriculture level.

JPIAMR main ambition is to reduce AMR by aligning resources and supporting scientific activities at international level to **provide evidence-based solutions** to the policy level; at public health and veterinarian/agriculture level.

JPIAMR does:

- **Coordinate funding strategies**
- **Coordinate national funds and transnational funds**
- **Joint funding in major pots**
- **Prioritise and define research questions**
- **Design top down funding decisions**
- **Filling key gaps in knowledge to support drug discovery and prevention and conservation strategies**
- **Align national and international AMR strategies and research plans**

2. Implementation plan and instruments

In order to organise the portfolio of joint strategic activities the JPIAMR MB has developed the “Implementation Plan 2014-2018”. This document covers both the implementation of the Strategic Research Agenda priority topics and of the supporting strategic actions as well as the following key instruments:

- Instruments for Strategic Research Agenda Delivery
 - Supporting Research, Supporting resources, Supporting Capacity building in AMR field, Supporting Development of the SRA and exploration of emerging topics in the field of AMR
- Instruments for Alignment of Antimicrobial Resistance Activities
- Instruments for Evaluation Activities
- Instruments for Internationalisation and Cooperation
- Instruments for developing Industry Relations


The Management Board has set 7 working groups that will manage the long term strategic planning of the JPI as well as the implementation of the activities that conducts the Secretariat.

Major Achievements

Key achievement: Aligned resources by creating a collaborative platform, maximising existing and future efforts to combat AMR.

- **Strategic Research Agenda with adoption of One Health approach.** A Strategic Research Agenda and an Implementation Plan has been launched with the adoption of a One Health Approach. It is also the basis of the development of the WHO Global AMR Research Agenda.
- The development of **AMR national alignments** (through setting one health **national expert panels** that helps to articulate the national research community and **intergovernmental mirror groups** that helps to align the national programming) and **AMR plans and strategies** (from 2 countries having plans to 22 countries today) and adopted their national plans to the joint Strategic Research Agenda. It also has promote the launch of **new national AMR research programmes** in several countries.
- A **mapping exercise of AMR research** and associated investment in participating countries was performed and published as an article in “The Lancet”. It was a strong structural effect in the member countries to have a national overview of its AMR research capacity, identify gaps and its results are available online with an **AMR projects database**.
- Strategic scoping, increasing internationalization of **research prioritisation**. Three international conferences, ten strategic workshops, several high level events with related initiatives and a variety of workshops have been organised (from the 13 major events only 4 have been co-funded by the EC)

- **Funding research that make impact and add value.** The commitment of up to 55 million Euro of funding for four joint transnational calls during the period of 2014-2016 was secured. Including a Research Network programme and 1 Eranet co-fund. 3 more joint calls, including a fellowship programme are in the pipeline. JPIAMR is attracting more researchers into this field, increasing critical mass and international scientific cooperation.
- **Coordinating research priorities and calls with the EC, IMI and the pharma industry,** through a specific working group, regular meetings and joint workshops. JPIAMR takes part of the industry future funding decisions by participating in the IMI2 Strategic Group on Infectious Diseases and the joint group EFPIA-IMI-EC-JPIAMR. It has also **contributed to the international antibiotic pipeline** by co-organising the first “Transatlantic Clinical Trials Workshop in the area of AMR” (Jan. 2016) and an “Early antibiotic discovery workshop” (Jan. 2017)
- JPIAMR is proving to be an **international platform** by extending membership beyond Europe - Japan, Argentina and Canada has joined (South Africa is applying) and by engaging with international stakeholders such as WHO, USA (through NIH and TATFAR with joint workshops), ASEAN (workshops and potential new call) and G7. JPIAMR activities are included in the G7 and G20 AMR declarations, in the WHO AMR Global Action Plan and in the latest UN AMR resolution. We work closely with EC DG Research and Also with DG Sante with an AMR Joint Action and in the implementation of EU AMR Action Plan.



JPIAMR's 22 member countries.

Status Note: Since 2013, the governance structure of JPIAMR was established, a Strategic Research Agenda 2013 and an Implementation Plan 2014-18 were launched with the adoption of a One Health Approach. A Central Secretariat has been built. A Terms of Reference document, a Vision Document, an Alignment Plan 2015, an AMR research funding mapping 2015 and other strategic and governance documents such as evaluation and monitoring framework 2014, peer review guidelines 2014, IPR and Open Access policy 2016, foresight guidelines 2014 and a communication strategy 2015 were developed. A self-evaluation was also undertaken in 2015.

4. Topics and activities of 2018-20 plans

JPIAMR current Implementation plan runs only until 2018. The JPI has planned to start the design of its next Implementation plan during the year 2017 as done previously with a combination of methods of exploratory workshops, surveys and policy meetings. We are going to develop 6 roadmap workshop by of the pillars of the Strategic Research Agenda in order to scope, map and develop a set of call topic and other activities priorities by pillar.

As major activities:

- **Set up a virtual institute.**
- **Issue a Prevention call in 2017.**
- **Issue a Fellowship grant call in 2017-18.**
- **Issue a joint call in Surveillance in 2018 (topic identification under development)**
- **Issue a joint call in new Compounds identification in 2018 (topic identification under development)**
- **Set up a new Eranet cofund in 2019 in the area of Interventions (topic identification under development)**
- **Issue several policy calls to set new Working Groups/Research Networks**
- **Reinforce discussions with industry regarding bridging the gap between pre-clinical and clinical: feeding the antibiotic pipeline.**
- **Update the Strategic Research Agenda – defining new research priorities.**
- **Active involvement in the SG Sante AMR Joint Action to define together the research needs of the public health authorities.**
- **Work internationally in the potential development of an AMR Global Fund.**
- **Set up high profile scientific workshops.**

Major areas of work:

- develop a long-term strategic plan including a sustainable governance structure with a business plan for the JPIAMR activities.
- widen the participation of European and non-European countries in JPIAMR activities and expand the membership globally.
- enhance the existing relations with national research and health policymakers, supranational AMR initiatives, and industry in order to align objectives and assess needs and identify areas for increased research funding.
- support the AMR research community by updating the SRA, providing support for an AMR virtual research institute, and providing information on, and facilitate use of infrastructures.
- collaborate with national funding agencies and research performing institutions and support them in the alignment of their activities to the SRA.
- increase the visibility and knowledge of JPIAMR initiative and its funded projects
- continuous mapping: setting up a Peer Review Database and a research input and output database.
- continue with a series of strategic workshops.

5. Proposed cooperation with EC and H2020

JPIAMR has already started discussions with the EC and the Health programme committee regarding the launch of a co-funded action in 2019. Discussions are the need to address underfunded areas on Antimicrobial resistance research especially in more interdisciplinary areas.

Negotiations have started to design an ERA-net Cofund for 2019 in the topic area of prevention, control and interventions.

Annex

Support from the Framework programme (including WP 2016/17)			
Coordination and support actions			
JPIAMR	September 2012 – March 2015	Total costs: 2.47 Million Euro	Union contribution: 2 Million Euro
EXEDRA	Proposal submitted in spring 2016	Potential Total costs: 2.50 Euro million	Requested Union contribution: 2 Million Euro
ERA-NET, ERA-NET Plus, ERA-NET Cofund			
JPI-EC-AMR	2015 – 2020	Total costs: 28,4 Million EUR	Union contribution: 5 Million EUR
Public funding mobilised until 12/2017			
Transnational activities Total volume of initiated activities		- Only competitive funding grants: EC on AMR (2007-2013): €314,072,980 IMI on AMR (2007-2013): €345,128,438 JPIAMR (2014-2016): 56 M EUR -It is not considered all the in-kind contributions in setting workshops, conferences, meetings, time staff in-kind to the Secretariat, etc.	
National calls and other activities calls Total public funding implemented/published		The JPIAMR MS at national level have invested on Antibiotic Resistance (on competitive funding projects) €646,646,541 from 2007-2013. Institutional level funding of research centres and infrastructures are not yet being surveyed. We do not have the information at this moment.	

Transnational calls JPI Total public funding implemented/published	Call no 1 InnovaResistance: 8.1 Million EUR Call no 2 Repurposing of neglected AB: 4.5 Million EUR Call no 3 Transmission (ERAnet Cofund call): 28.4 Million EUR Call no 4 WGs/Research Networks: 0,650 Million EUR Call no 5 Interventions: aprox. 15 Million EUR (under negotiation) Call no 6 Fellowships: (under negotiation) TOTAL: 56 Million EUR
---	---